Monoclonal antibodies can block a key immune‑related protein that drives the spread of brain cell damage in Parkinson’s disease (PD).
Antibodies targeting GPNMB may slow Parkinson’s disease progression
- Post author:admin
- Post published:
- Post category:uncategorized